Literature DB >> 12848623

Review article: mitogen-activated protein kinases in chronic intestinal inflammation - targeting ancient pathways to treat modern diseases.

G H Waetzig1, S Schreiber.   

Abstract

Conventional treatment of chronic inflammatory disorders, including inflammatory bowel diseases, employs broad-range anti-inflammatory drugs. In order to reduce the side-effects and increase the efficacy of treatment, several strategies have been developed in the last decade to interfere with intercellular and intracellular inflammatory signalling processes. The highly conserved mitogen-activated protein kinase pathways regulate most cellular processes, particularly defence mechanisms such as stress reactions and inflammation. In this review, we provide an overview of the current knowledge of the specificity and interconnection of mitogen-activated protein kinase pathways, their functions in the gut immune system and published and ongoing studies on the role of mitogen-activated protein kinases in inflammatory bowel disease. The development of mitogen-activated protein kinase inhibitors and their use for the therapy of inflammatory disorders is a paradigm of the successful bridging of the gap between basic research and clinical practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12848623     DOI: 10.1046/j.1365-2036.2003.01642.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Cell-specific inhibition of p38alpha as a therapeutic strategy for inflammatory bowel disease.

Authors:  Eóin N McNamee; Colm B Collins; Matthew D P Lebsack; Jesús Rivera-Nieves
Journal:  Gastroenterology       Date:  2010-02-23       Impact factor: 22.682

2.  β-Cryptoxanthin supplementation prevents cigarette smoke-induced lung inflammation, oxidative damage, and squamous metaplasia in ferrets.

Authors:  Chun Liu; Roderick T Bronson; Robert M Russell; Xiang-Dong Wang
Journal:  Cancer Prev Res (Phila)       Date:  2011-03-18

3.  Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease.

Authors:  Motoyuki Otsuka; Young Jun Kang; Jianlin Ren; Huiping Jiang; Yinbin Wang; Masao Omata; Jiahuai Han
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

4.  FR167653, a p38 mitogen-activated protein kinase inhibitor, aggravates experimental colitis in mice.

Authors:  Takashi Nishimura; Akira Andoh; Atsushi Nishida; Makoto Shioya; Yuhsuke Koizumi; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

Review 5.  Role of the JNK signal transduction pathway in inflammatory bowel disease.

Authors:  Praveen K Roy; Farzana Rashid; Jack Bragg; Jamal A Ibdah
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

6.  The potential probiotic Lactobacillus rhamnosus CNCM I-3690 strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response.

Authors:  Rebeca Martín; Celia Chamignon; Nadia Mhedbi-Hajri; Florian Chain; Muriel Derrien; Unai Escribano-Vázquez; Peggy Garault; Aurélie Cotillard; Hang Phuong Pham; Christian Chervaux; Luis G Bermúdez-Humarán; Tamara Smokvina; Philippe Langella
Journal:  Sci Rep       Date:  2019-04-01       Impact factor: 4.379

7.  Insight into the Structural Determinants of Imidazole Scaffold-Based Derivatives as TNF-α Release Inhibitors by in Silico Explorations.

Authors:  Yuan Wang; Mingwei Wu; Chunzhi Ai; Yonghua Wang
Journal:  Int J Mol Sci       Date:  2015-08-25       Impact factor: 5.923

8.  Identification and Characterization of MAPK Signaling Pathway Genes and Associated lncRNAs in the Ileum of Piglets Infected by Clostridium perfringens Type C.

Authors:  Ruirui Luo; Xiaoyu Huang; Zunqiang Yan; Xiaoli Gao; Pengfei Wang; Qiaoli Yang; Wei Wang; Kaihui Xie; Shuangbao Gun
Journal:  Biomed Res Int       Date:  2020-08-12       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.